Quarterly combined revenue and operating EBITDA are higher
Revenue and operating profit grew on comparable issuer pro-forma basis
Watch: Verify the statutory-to-operating bridge
Home / Research / Aster DM Quality Care Limited
Quarterly combined revenue and operating EBITDA are higher
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e24346d6-2631-403e-8dba-020c04b7c8c4.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e24346d6-2631-403e-8dba-020c04b7c8c4.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e24346d6-2631-403e-8dba-020c04b7c8c4.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e24346d6-2631-403e-8dba-020c04b7c8c4.pdf
Revenue and operating profit grew on comparable issuer pro-forma basis
Watch: Verify the statutory-to-operating bridge
Growth reflects utilization and mix, with excluded expenses
Watch: Check adjustment consistency
Do not compare with unadjusted statutory EBITDA
Watch: Monitor recurring margin
Exceptional merger costs are excluded
Watch: Demand a statutory bridge
Aster DM Quality Care | Q2 FY27 | Quarter ended 30 September 2026 | Stance: WATCH. The first complete operating quarter after the merger is an unusually informative but accounting-complex baseline. Management's combined, like-for-like presentation reports revenue of ₹2,829 crore (+19% year on year), operating EBITDA of ₹678 crore (+25%), operating margin of 24.0% (+111 basis points), and normalized profit after non-controlling interests of ₹281 crore (+34%). These are NOT statutory year-on-year growth comparisons: the merger became effective 1 July 2026, and prior statutory comparatives were not restated. The issuer constructed pro-forma combined prior-period figures to show economic momentum. [S1]
Decision in 30 seconds. WATCH the network's ability to turn occupancy, clinical complexity and procurement synergies into recurring cash after expansion spending. Do not equate the reported 24% operating margin with statutory EBITDA or the normalized ₹281 crore with statutory profit. No stock price, market capitalization, enterprise value or valuation multiple is supplied by the accepted sources; a defensible entry price cannot be calculated here. A valuation premium would require repeatable cash conversion, sustained patient growth and capital-efficient bed commissioning, rather than a single integration quarter.
Key quantified takeaways:
What could change the view: a sustained rise in occupancy and revenue per operating bed without an offsetting jump in clinical staffing and equipment costs; measurable net-debt discipline while commissioning the pipeline; and evidence that merger savings remain after the initial low-hanging procurement efficiencies. The following seven chapters distinguish reported issuer figures, management targets and our conditional interpretation.
The investment case rests on three interacting engines: more patients treated in existing hospitals, greater complexity of treatment per patient, and scale benefits from combining Aster, CARE, KIMSHEALTH and Evercare. Each engine can reinforce the others, but each can also disappoint independently. Q2 showed strong patient demand with relatively modest operational bed additions, suggesting that the near-term improvement was not solely a capacity effect. Yet occupancy of 68% still leaves room for utilization gains before the next large commissioning cycle. [S1]
Investment decision: maintain WATCH rather than imply a buy at an unknown market price. The appropriate valuation question is whether incremental operating profit can finance the coming 4,230-bed program without deteriorating leverage or diluting return on capital. The issuer's 23.0% quarter ROCE uses a defined capital-employed denominator excluding several categories including work in progress, goodwill and intangibles; it is not directly interchangeable with an all-in economic return on invested capital. [S1]
Tests before paying a premium:
The principal reason to hesitate is not a lack of growth; it is the interaction of pro-forma comparisons, new-hospital ramp costs, and large planned capital commitments. A quarterly improvement in operating EBITDA is encouraging but does not alone establish equity value creation.
The issuer presentation supplies an explicitly combined pro-forma comparative for Q2 FY26. Against that basis, revenue increased from ₹2,382 crore to ₹2,829 crore; operating EBITDA from ₹545 crore to ₹678 crore; and normalized post-NCI PAT from ₹210 crore to ₹281 crore. Operating EBITDA margin advanced from 22.9% to 24.0%.
The operating EBITDA series excludes other income and, for Q2 FY27, certain ESOP costs, variable O&M fees and other expenses. Normalized PAT excludes merger-related exceptional expenses and the share of loss from equity-accounted investees. These exclusions are economically material when assessing the sustainability of the stated profit margin. [S1]
| Measure | Q2 FY26 combined pro forma | Q2 FY27 combined | Interpretation |
|---|---|---|---|
| Revenue (₹ crore) | 2,382 | 2,829 | +19% on issuer's combined basis |
| Operating EBITDA (₹ crore) | 545 | 678 | +25%; issuer-defined operating metric |
| Operating EBITDA margin | 22.9% | 24.0% | +111 basis points, issuer rounding |
| Normalized PAT after NCI (₹ crore) | 210 | 281 | +34%; not statutory PAT |
| Patient volume (million) | 1.95 | 2.18 | +12% |
| Operational beds | 10,222 | 10,611 | +4% |
| Occupancy | 65% | 68% | +335 basis points before rounded display |
Half-year performance: management reports H1 FY27 combined revenue of ₹5,429 crore (+20%), operating EBITDA ₹1,255 crore (+27%), operating margin 23.1% (versus 21.8%) and normalized post-NCI PAT ₹457 crore (+27%). These are issuer-defined combined comparisons, not restated statutory historical statements. [S1]
Earnings-quality questions:
The most important accounting caveat is specific: Quality Care entered the reported consolidated results on 1 July 2026 under pooling of interests, but prior reported periods were not restated. Readers should not calculate statutory YoY growth from the presented combined pro-forma numbers.
The operating story is about increasing throughput and higher-acuity procedures across a network of brands rather than merely adding buildings. Total Q2 patient volume reached approximately 2.18 million, while the operational bed base grew just 4%. The issuer reports a 335-basis-point occupancy improvement to 68%, supporting fixed-cost absorption across hospitals. Average length of stay was 3.3 days in both comparative quarters, so the occupancy improvement is not simply a longer-stay artifact. [S1]
Maturity matters. Mature hospitals represented approximately 64% of operational beds but produced 73% of hospital revenue and 83% of operating EBITDA in the H1 mix described by management. Their revenue grew 18% and patient volume 11%. Focus hospitals represented 15% of beds and revenue, with 13% revenue growth and 7% volume growth. Emerging hospitals represented around 10% of beds and 6% of revenue, but reported 62% revenue growth and 53% volume growth from a smaller base. Underperforming hospitals grew revenue 24% and more than doubled operating EBITDA according to management; no precise starting EBITDA is provided. [S1]
Complex care: robotic surgeries grew 39%, kidney transplants 31% and joint replacements 29% in the period management described. These are activity growth rates, not segment revenue or margins; the accepted presentation does not permit assigning specific incremental profits to each procedure type. Medical value travel revenue grew 36% year on year, with Maldives and Gulf markets prominent and West Africa and other MENA markets contributing. [S1]
Economic implications:
The company operates across 27 cities and reports 10,840 capacity beds, distinct from 10,611 operational beds. The difference is important: a capacity bed is not automatically staffed, commissioned or earning revenue.
The merger's first 100 days were framed around preserving clinical continuity while integrating purchasing, clinical talent and operating practices. Management reported 2.2 million patients served, no disruption to patient care, and a broad effort to standardize performance across four hospital brands. These are management statements; the next proof point is measurable unit economics rather than cultural integration slogans. [S1]
The Q2 synergy achievement was ₹16.6 crore, which management annualized to about ₹65 crore. In analyst Q&A, executives described a potential ₹200 crore full synergy opportunity, with an ambition to reach that level on an annualized run-rate basis over roughly the next three to four quarters; actual full realization could take longer. That timing is management guidance, not reported earnings. Procurement, medical material costs, clinical sharing, indirect spending, F&B insourcing, IT and energy efficiency were identified as levers. The company did not provide a reliable rupee allocation by lever. [S1]
Milestones to monitor:
Analyst challenge: a question on whether centralized procurement would produce 10% or 20% savings did not receive a precise disclosed savings percentage. Management instead emphasized the wider synergy wheel. Therefore, do not model an unsupported fixed procurement-margin improvement. Another question probed the timing of ₹200 crore synergy potential; the response distinguished run-rate attainment from full realized benefits. Investors should make that distinction in each future quarter.
At 30 September 2026, management reported gross debt of ₹3,959 crore and cash, bank balances and current investments of ₹2,240 crore, implying net debt of ₹1,719 crore. Management's trailing-twelve-month net debt/EBITDA was 0.87 times excluding lease liabilities and 1.72 times including leases. Those ratios use different liability bases and should not be conflated. [S1]
The combined network invested approximately ₹400 crore in H1 FY27 capex, mainly on ongoing projects with the balance on medical equipment. Management also referenced more than ₹1,200 crore of project, growth and refresh capex over the preceding 18 months. Neither figure is a free-cash-flow measure. The source excerpts do not provide a fully reconciled operating cash flow, maintenance capex, working capital bridge or project-level payback schedule; a precise cash-conversion ratio and IRR would be invented. [S1]
Expansion financing discipline: the stated 4,230-bed pipeline comprises roughly 47% brownfield and 53% greenfield capacity. Brownfield additions may leverage existing referrals, infrastructure and brand recognition; greenfield facilities typically require a longer occupancy ramp. These are economic hypotheses, not management-certified returns. The network's current 10,840 capacity beds and 10,611 operational beds must not be added to the pipeline indiscriminately when measuring future occupancy. [S1]
Capital tests:
The central risk is a temporary mismatch between capex cash outflows and the contribution from new beds. A margin-led investment thesis can still fail if cash investment rises faster than durable hospital cash generation.
Bull case, conditional: patient growth remains well above operational bed additions, the higher-acuity case mix persists, mature units sustain margin expansion, and realized synergy savings progress toward management's ₹200 crore potential without being offset by rising clinical staffing and integration costs. Occupancy stays firm while new capacity is absorbed. This would strengthen the argument for a quality premium, but the sources do not establish a price target or multiple. [S1]
Base case, conditional: the company maintains healthy demand and continues to open new units, but integration benefits emerge unevenly and the incremental margin from mature hospitals is partly consumed by early-stage greenfield costs. Operating EBITDA still grows, but cash conversion and net debt remain the decisive valuation checks. The reported Q2 24.0% operating margin should not be extrapolated mechanically through an expansion cycle. [S1]
Bear case, conditional: medical equipment and project spending remain elevated, new units take longer to fill, procurement savings plateau, or staff and doctor retention costs rise. In this scenario, reported patient growth may coexist with weaker returns on capital and higher lease-adjusted leverage. The bearish thesis is falsified if future filings demonstrate both improved cash conversion and a profitable ramp at new facilities.
Quantified anchor points, not forecasts: 68% occupancy; 10,611 operational beds; ₹1,719 crore net debt; ₹400 crore H1 capex; ₹16.6 crore realized quarterly synergies; and 4,230 planned beds. No assumed annual revenue growth, terminal multiple, equity price or earnings forecast has been inserted. Each scenario describes the conditions investors should test rather than assigning unsupported probabilities.
Falsifiers to track:
The largest uncertainty is the economic cost of integration and expansion, not the arithmetic of the headline growth figures.
Current action: WATCH, with a quarterly evidence checklist rather than a speculative entry price. The next release should be read against the same combined/pro-forma basis, with a separate bridge to statutory consolidated earnings. Ask management to reconcile operating EBITDA adjustments and normalized post-NCI profit with reported accounting results before using either as a valuation numerator. [S1]
| Monitor | Q2 FY27 issuer baseline | Decision use |
|---|---|---|
| Combined revenue | ₹2,829 crore | Separate volume from pricing and mix |
| Operating EBITDA margin | 24.0% | Check adjustment consistency and mature-unit economics |
| Patient volume | 2.18 million | Test demand versus operational bed additions |
| Occupancy | 68% | Test utilization and operating leverage |
| Capacity / operational beds | 10,840 / 10,611 | Track conversion to earning beds |
| Net debt | ₹1,719 crore | Compare with actual capex and cash generation |
| Lease-inclusive net debt/EBITDA | 1.72x | Watch full financing burden |
| Realized quarterly synergies | ₹16.6 crore | Verify sustainable integration benefits |
| Pipeline | 4,230 beds | Monitor commissioning and payback |
Next-quarter action tests:
Investment conclusion: the merger has produced credible initial scale and operating-leverage signals, but the value-creation test is still ahead. Q2 demonstrates demand and a promising integration start; the investment decision requires verified cash conversion and sustained post-expansion returns. No current market price or independent valuation is included in the accepted source set, so this is a monitoring plan, not a buy/sell or price-target call.
[S1] BSE investor presentation for Q2 and H1 FY27, filed 6 November 2026. This filing contains the issuer's financial, operating, capacity and synergy exhibits. The associated 6 November management earnings discussion was used for Q&A interpretation; its internally accepted text is not reproduced or linked to a third-party transcript host. The original issuer/exchange transcript URL was not available in the accepted source ledger. The document provenance and text fingerprints remain private. The issuer explicitly uses combined pro-forma historical comparatives and adjusted operating-profit definitions. Full project-level cash payback, statutory cash-flow reconciliation and live valuation inputs are not provided in the extracted evidence used for this report.
[S2] Management earnings-call transcript, 6 November 2026 (internally archived full text). The original issuer-hosted transcript URL was not available; this source is identified for provenance but is not linked to a third-party mirror.
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e24346d6-2631-403e-8dba-020c04b7c8c4.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e24346d6-2631-403e-8dba-020c04b7c8c4.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e24346d6-2631-403e-8dba-020c04b7c8c4.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e24346d6-2631-403e-8dba-020c04b7c8c4.pdf
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.